Olema announces updated data on Phase 1b/2 study of palazestrant, ribociclib

Olema Pharmaceuticals announced updated data from the Phase 1b/2 study of palazestrant in combination with ribociclib in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. These findings will be presented in a poster session on October 20 at the European Society for Medical Oncology, ESMO, Congress 2025 in Berlin, Germany. Key Findings from the Phase 1b/2 Study of Palazestrant in Combination with Ribociclib: Efficacy: In the 90 mg palazestrant dose cohort, with a median follow-up of 10.8 months, median progression-free survival was not reached. In the 120 mg palazestrant dose cohort, with a median follow-up of more than 19 months, median PFS are mature. Median PFS was 15.5 months for all patients. Safety and Pharmacokinetics: Across 72 patients treated, 90 mg or 120 mg of palazestrant combined with 600 mg of ribociclib daily was well tolerated with no new safety signals or increase in toxicity. Palazestrant and ribociclib did not demonstrate any drug-drug interactions and the overall safety profile was consistent with the established safety profile of ribociclib plus an endocrine therapy